Tag: Canakinumab

Both ILARIS and Kineret are powerful biologic medications that target the inflammatory protein interleukin-1 (IL-1), but they have distinct mechanisms and clinical applications. While both can treat certain autoinflammatory conditions, understanding what is the difference between ILARIS and Kineret is critical for patients and healthcare providers. This comparison covers the crucial variances in their function, indications, and dosing frequency.

The list price for a single 150mg vial of Ilaris can exceed $20,000 in the US, but the amount a patient ultimately pays varies widely. Understanding how much does Ilaris cost in the US involves looking beyond the high sticker price to navigate a complex system of insurance, dosage requirements, and financial assistance programs.

With some reports indicating an annual cost upwards of $73,000, Canakinumab (sold under the brand name Ilaris) is a high-priced biologic medication. Understanding **what is the price of Canakinumab 150 mg** requires looking beyond the sticker price to consider insurance coverage, patient assistance, and the specific medical indication.

The medication canakinumab, marketed under the brand name Ilaris®, was first approved by the U.S. Food and Drug Administration (FDA) in June 2009. So, who makes canakinumab? The Swiss multinational healthcare company Novartis is the developer and manufacturer of this important biopharmaceutical.